Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Cash Flow (2016 - 2025)

Tg Therapeutics has reported Net Cash Flow over the past 10 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $5.1 million for Q4 2025, up 131.9% from a year ago — trailing twelve months through Dec 2025 was -$100.7 million (down 215.78% YoY), and the annual figure for FY2025 was -$100.7 million, down 215.78%.
  • Net Cash Flow for Q4 2025 was $5.1 million at Tg Therapeutics, up from -$55.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TGTX hit a ceiling of $112.9 million in Q3 2024 and a floor of -$113.2 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was -$32.4 million (2021), compared with a mean of -$23.7 million.
  • Biggest five-year swings in Net Cash Flow: crashed 1083.02% in 2021 and later soared 244.84% in 2023.
  • Tg Therapeutics' Net Cash Flow stood at -$27.6 million in 2021, then skyrocketed by 72.66% to -$7.6 million in 2022, then plummeted by 667.56% to -$58.0 million in 2023, then skyrocketed by 72.53% to -$15.9 million in 2024, then soared by 131.9% to $5.1 million in 2025.
  • The last three reported values for Net Cash Flow were $5.1 million (Q4 2025), -$55.0 million (Q3 2025), and -$3.0 million (Q2 2025) per Business Quant data.